治疗前中性粒细胞与淋巴细胞比值对小细胞肺癌患者预后的意义

Significance of pre-treament neutrophil-to-lymphocyte ratio on prognosis of small cell lung patients

目的探讨治疗前中性粒细胞与淋巴细胞比值(neutrophil/lymphocyte ratio,NLR)与小细胞肺癌(small cell lung cancer,SCLC)患者预后的关系。方法回顾性分析75例小细胞肺癌患者的临床资料。根据血常规结果计算NLR值,以中位NLR值3.18为最佳截断值,分为高NLR(≥3.18)组和低NLR(<3.18)组。比较高NLR组和低NLR组SCLC患者的临床特征及2组患者无进展生存期(progression free survival,PFS)和总生存时间(overall survival,OS)的差异,分析影响SCLC患者PFS和OS的因素。结果高NLR组的临床分期中广泛期的比例多于低NLR组,差异有统计学意义(P<0.05);高NLR组与低NLR组中位PFS分别为5.73个月和8.50个月,差异有统计学意义(P<0.05);高NLR组与低NLR组中位OS分别10.57个月和15.10个月,差异有统计学意义(P<0.05);Cox回归分析结果显示,临床分期、治疗前NLR水平是SCLC患者PFS和OS的影响因素。结论高NLR往往提示预后不良,是SCLC患者预后的影响因素,对于判断预后具有重要意义。

Objective To evaluate the correlation of pre-treament neutrophil/lymphocyte ratio(NLR)with the prognosis of patients with small cell lung cancer.Methods The clinical data of 75 small cell lung cancer with pathologically diagnose were retrospectively analyzed.Routine peripheral blood test results were used to calculate the NLR.The patients were divided into two groups(high NLR group and low NLR group)with the median value of NLR.The clinical features of high and low NLR group were compared.The differences of overall survival(OS)and progressive-free survival(PFS)were compared in the two groups.The factors affecting PFS and OS in SCLC patients were analyzed.Results The proportion of the high NLR group in extensive stages was higher than that of the low NLR group,and the difference was statistically significant(P<0.05).The median PFS of the high NLR group and the low NLR group was 5.73 months vs 8.50 months,respectively,and the difference was statistically significant(P<0.05).The median OS in the high NLR group and the low NLR group was 10.57 months and 15.10 months,respectively,with statistically significant differences(P<0.05).The Cox regression analysis showed that clinical stage and NLR level were prognostic factors.Conclusion High NLR often indicates poor prognosis,and it is an important prognostic factor and plays an important role in prognostic evaluation of SCLC patients.